A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies (Soundtrack-E)

• Drug: AZD0486
• Drug: Acalabrutinib
• Drug: Prednisone
• Drug: Rituximab
• Drug: Cyclophosphamide
• Drug: Vincristine
• Drug: Doxorubicin

Inclusion Criteria:

Master Inclusion Criteria applicable to all substudies:

• Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) performance status of 0 to 2.
• Contraception during treatment and at least 6 months after final dosethe amount of medication taken.
• Confirmed CD19 expression if prior anti-CD19 therapy.

Substudy 1 Specific Inclusion Criteria:

• Participants with CLL must require treatment according to the international workshop on Chronica long-lasting disease that changes slowly over time Lymphocytic Leukemia (iwCLL) criteria.
• SLL: at least 1 measurable site per Lugano.
• Absolute lymphocytes <10,000.
• Cohort 1A: at least 2 prior lines of therapy, including a Bruton tyrosine kinase inhibitor (BTKi) and B-cell lymphomacancers of the lymphatic system 2 inhibitor (BCL2i).
• Cohort 1B: at least 1 prior line of therapy and is BTKi-sensitive.

Substudy 2 Specific Inclusion Criteria:

• MCL diagnosisthe process of identifying a disease based on signs and symptoms, patient history and medical test results per WHO.
• Clinical Stage II, III, or IV by Ann Arbor Classification.
• At least 1 measurable site per Lugano
• ALC < 10,000.
• Cohort 2A: Relapsethe return of disease or progressed after 2 or more lines of therapy including BTKi.
• Cohort 2B: Relapse or progressed after 1 or more line of therapy, not including a BTKi.

Substudy 3 Specific Inclusion Criteria:

• Large B-cell lymphoma per WHO 2022.
• R/R B-NHL after at least 1 prior line of therapy.
• International Prognostic Index (IPI) 2-5.
• At least 1 measurable site as per Lugano.
• Left ventricular ejection fraction (LVEF) >50%.
• Contraception at least 12 months after last dose of R-CHOP or 6 months after last dose of AZD0486.